The JPMorgan Healthcare Conference is a place where deals happen. As the conference kicked off, deals were announced from Eli Lilly ( LLY ), Johnson & Johnson ( JNJ ), and GSK ( GSK ).

Maurits Pot, CEO of Tema ETFs, joins Market Domination to give his predictions for continued M&A growth, specifically within the oncology, neuroscience, and metabolic sectors.

Pot reflects on the challenges faced by the healthcare sector in 2024 and the outlook for the coming year.

"2024 was, again, a pretty muted year for healthcare M&A, overall, a muted year for the healthcare sector and a number of big companies did not do many big acquisitions," Pot's says. "We think there will be a material pick up this year."

Pot also discusses challenges in the GLP-1 market but cites innovation in drug delivery.

To watch more expert insights and analysis on the latest market action, check out more Market Domination here .

This post was written by Josh Lynch